Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
The Klinique Medical Clinic Public Company Limited (KLINIQ.BK)
Bangkok, TH
The Klinique Medical Clinic Public Company Limited, operating from its headquarters in Bangkok, Thailand, offers a comprehensive suite of services encompassing skin care, cosmetic surgery, and holistic health solutions. Their extensive portfolio of treatments includes a variety of aesthetic and medical procedures. These range from facial rejuvenation and contouring options like facelifts, dermal fillers, and fat-dissolving injections, to body sculpting using "shape up" treatments. The clinic also specializes in advanced dermatological care for issues such as acne and acne scars, alongside general skin enhancement therapies like laser hair removal, targeted skin injections, Mesoface, and meso treatments. Furthermore, they perform specialized surgical interventions for the nose, eyes, and other facial areas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.64% | -7.02% | +0.95% | +6.43% | +25.00% | +23.83% | +21.00% | -32.05% | +8.16% | +8.16% | +8.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Personal Products & Services: +6.6%+19.2% ★ Q1'26: +33.5% (vs Q1'25)
-
EPS growth Personal Products & Services: +19.6%+13.0% Q1'26: +41.0% (vs Q1'25)
-
FCF margin FCF growth · Personal Products & Services: +11.7%+19.1% Q1'26: +23.2% (vs Q1'25)
-
EBIT margin Personal Products & Services: +10.5%+13.0% ★ Q1'26: +14.3% (vs Q1'25)
-
ROIC Personal Products & Services: +6.9%+16.0% ★ Q1'26: +27.9% (vs Q1'25)
-
Share dilution Personal Products & Services: +0.0%+0.0% Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Personal Products & Services: 0.59×1.55× Q1'26: 0.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.64B
est: 1.48B (+11.0%)
|
2.28B
est: 2.63B (-13.0%)
|
2.98B
est: 2.94B (+1.6%)
|
3.56B
est: 3.49B (+1.8%)
|
4.18B
4.13B – 4.25B
+19.6% YoY
|
4.69B
4.64B – 4.73B
+12.1% YoY
|
5.36B
5.31B – 5.43B
+14.5% YoY
|
| EBITDA |
397.75M
est: 357.68M (+11.2%)
|
559.93M
est: 623.93M (-10.3%)
|
689.20M
est: 697.94M (-1.3%)
|
791.36M
est: 830.35M (-4.7%)
|
993.12M
982.07M – 1.01B
+19.6% YoY
|
1.11B
1.10B – 1.12B
+12.1% YoY
|
1.27B
1.26B – 1.29B
+14.5% YoY
|
| EBIT |
255.75M
est: 231.77M (+10.3%)
|
365.32M
est: 392.14M (-6.8%)
|
414.82M
est: 438.66M (-5.4%)
|
463.77M
est: 521.87M (-11.1%)
|
624.17M
617.23M – 634.27M
+19.6% YoY
|
699.77M
693.46M – 706.08M
+12.1% YoY
|
801.13M
793.10M – 811.07M
+14.5% YoY
|
| Net Income |
205.49M
est: 193.60M (+6.1%)
|
288.62M
est: 298.30M (-3.2%)
|
322.19M
est: 307.93M (+4.6%)
|
363.70M
est: 359.16M (+1.3%)
|
394.43M
387.38M – 421.56M
+9.8% YoY
|
433.85M
428.63M – 474.47M
+10.0% YoY
|
535.15M
504.39M – 565.91M
+23.3% YoY
|
| SGA |
674.28M
est: 606.16M (+11.2%)
|
903.07M
est: 1.05B (-13.9%)
|
1.15B
est: 1.17B (-1.7%)
|
1.33B
est: 1.40B (-4.5%)
|
1.67B
1.65B – 1.70B
+19.6% YoY
|
1.87B
1.85B – 1.89B
+12.1% YoY
|
2.14B
2.12B – 2.17B
+14.5% YoY
|
| EPS |
0.93
est: 0.88 (+5.7%)
|
1.31
est: 1.36 (-3.4%)
|
1.46
est: 1.40 (+4.5%)
|
1.65
est: 1.63 (+1.2%)
|
1.86
1.76 – 1.92
+14.0% YoY
|
2.05
1.95 – 2.16
+10.5% YoY
|
2.43
2.29 – 2.57
+18.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Weerasak Sinsapphaiboon | MD & Executive Director | 279.5K | male |
| Apiruj Thongwattana | Chief Executive Officer & Executive Director | 211.4K | male |
| Ratthaphon Kittichaitrakul | MD, Chief Operating Officer, Chief Support Officer & Executive Director | 125.0K | male |
| Natthapat Chalisarapong | Chief Marketing Officer | — | male |
| Mongkon Laoworapong | Head of Internal Audit | — | — |
| Athikom Wongsongcha | Chief Accounting & Financial Officer | — | male |
| Apiphan Charoenanusorn | Executive Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KLINIQ.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
